Zessly

Zessly (infliximab) is a biologic medication used to reduce inflammation in conditions like rheumatoid arthritis and Crohn's disease. As an intravenous infusion, it targets specific immune pathways to help manage chronic inflammatory disorders. This biosimilar offers an alternative to reference biologics for targeted therapy.

Infliximab, the active ingredient in Zessly, is prescribed to treat moderate to severe inflammatory conditions. It is commonly used for autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Zessly may also be used for Crohn's disease and ulcerative colitis when other treatments have not been effective. Patients often ask, 'What is infliximab used for?' to understand its role in managing chronic inflammation.

Zessly works by binding to TNF-alpha, a protein involved in inflammation, helping to reduce symptoms like joint pain and swelling. Many patients notice an improvement in mobility and daily functioning after starting treatment. The effects of infliximab can vary, and it may take several weeks to see noticeable changes in symptoms.

Zessly is administered by healthcare professionals in a controlled setting due to the risk of infusion reactions. Patients should inform their provider about any infections or recent vaccinations before starting treatment. Regular monitoring may be required to assess response and detect potential side effects early.

Infliximab can interact with other medications that affect the immune system, such as corticosteroids or other biologics. Live vaccines should be avoided during treatment with Zessly due to the risk of infection. Patients should discuss all current medications with their healthcare provider to minimize potential interactions.